FZ1 peptide

FZ1 peptide (10 nM) shows the highest drug loading content (12.26%) and drug loading efficiency (83.12%) among all tested formulations when incorporated into the 4% (w/v) HA-c-FZ1 hydrogel^[1].
FZ1 peptide (2-4% (w/v)) is released from HA-c-FZ1 hydrogel in a pH-dependent manner, with an accelerated release rate under acidic conditions matching the early inflammatory phase of diabetic wounds, which supports pathologically coupled peptide delivery^[1].
FZ1 peptide (2-4% (w/v); 24 h) shows no cytotoxicity to HaCaT keratinocytes, HSFs, RAW264.7 macrophages and HUVECs in HA-c-FZ1 hydrogel extracts, and the 4% formulation significantly promotes cell proliferation^[1].
FZ1 peptide (4% (w/v)) activates the pro-angiogenic signaling pathways of ERK, AKT, and FAK in HUVECs within HA-c-FZ1 hydrogel extracts^[1].
FZ1 peptide (2-4% (w/v)) exhibits antibacterial activity against S. aureus and E. coli in extracts of HA-c-FZ1 hydrogels; it inhibits LPS-induced secretion of proinflammatory cytokines (IL-6, TNF-α) in RAW264.7 macrophages in a concentration-dependent manner; it reduces intracellular ROS levels in H₂O₂-treated HUVECs in a concentration-dependent manner; and it promotes migration of HaCaT keratinocytes and increases the healing rate of scratch wounds^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.